BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 28878238)

  • 21. APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition.
    Buisson R; Lawrence MS; Benes CH; Zou L
    Cancer Res; 2017 Sep; 77(17):4567-4578. PubMed ID: 28698210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer.
    Xu F; Liu T; Zhou Z; Zou C; Xu S
    Front Immunol; 2021; 12():749369. PubMed ID: 34745121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. APOBEC3A/B deletion polymorphism and endometrial cancer risk.
    Sofiyeva N; Krakstad C; Halle MK; O'Mara TA; Romundstad P; Hveem K; Vatten L; Lønning PE; Gansmo LB; Knappskog S
    Cancer Med; 2023 Mar; 12(6):6659-6667. PubMed ID: 36394079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ultra-deep targeted sequencing of advanced oral squamous cell carcinoma identifies a mutation-based prognostic gene signature.
    Chen SJ; Liu H; Liao CT; Huang PJ; Huang Y; Hsu A; Tang P; Chang YS; Chen HC; Yen TC
    Oncotarget; 2015 Jul; 6(20):18066-80. PubMed ID: 25980437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer.
    Serebrenik AA; Argyris PP; Jarvis MC; Brown WL; Bazzaro M; Vogel RI; Erickson BK; Lee SH; Goergen KM; Maurer MJ; Heinzen EP; Oberg AL; Huang Y; Hou X; Weroha SJ; Kaufmann SH; Harris RS
    Clin Cancer Res; 2020 Jul; 26(13):3397-3407. PubMed ID: 32060098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. APOBEC3A catalyzes mutation and drives carcinogenesis in vivo.
    Law EK; Levin-Klein R; Jarvis MC; Kim H; Argyris PP; Carpenter MA; Starrett GJ; Temiz NA; Larson LK; Durfee C; Burns MB; Vogel RI; Stavrou S; Aguilera AN; Wagner S; Largaespada DA; Starr TK; Ross SR; Harris RS
    J Exp Med; 2020 Dec; 217(12):. PubMed ID: 32870257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutational impact of APOBEC3A and APOBEC3B in a human cell line and comparisons to breast cancer.
    Carpenter MA; Temiz NA; Ibrahim MA; Jarvis MC; Brown MR; Argyris PP; Brown WL; Starrett GJ; Yee D; Harris RS
    PLoS Genet; 2023 Nov; 19(11):e1011043. PubMed ID: 38033156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3'UTR enhances chromosomal DNA damage.
    Caval V; Suspène R; Shapira M; Vartanian JP; Wain-Hobson S
    Nat Commun; 2014 Oct; 5():5129. PubMed ID: 25298230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma.
    Faden DL; Thomas S; Cantalupo PG; Agrawal N; Myers J; DeRisi J
    Oral Oncol; 2017 Nov; 74():8-14. PubMed ID: 29103756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of AKR1B10 as an independent marker for poor prognosis in human oral squamous cell carcinoma.
    Ko HH; Cheng SL; Lee JJ; Chen HM; Kuo MY; Cheng SJ
    Head Neck; 2017 Jul; 39(7):1327-1332. PubMed ID: 28301069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytidine Deaminase APOBEC3A Regulates PD-L1 Expression in Cancer Cells in a JNK/c-JUN-Dependent Manner.
    Zhao K; Zhang Q; Flanagan SA; Lang X; Jiang L; Parsels LA; Parsels JD; Zou W; Lawrence TS; Buisson R; Green MD; Morgan MA
    Mol Cancer Res; 2021 Sep; 19(9):1571-1582. PubMed ID: 34045311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The status of EGFR CA SSR1 is a potential prognostic factor for patients with oral squamous cell carcinoma.
    Lin YL; Wang WY; Lin JC; Wong YK; Chien YC
    Oral Oncol; 2011 Jun; 47(6):482-6. PubMed ID: 21530363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic Polymorphisms Predisposing the Interleukin 6-Induced APOBEC3B-UNG Imbalance Increase HCC Risk via Promoting the Generation of APOBEC-Signature HBV Mutations.
    Liu W; Wu J; Yang F; Ma L; Ni C; Hou X; Wang L; Xu A; Song J; Deng Y; Xian L; Li Z; Wang S; Chen X; Yin J; Han X; Li C; Zhao J; Cao G
    Clin Cancer Res; 2019 Sep; 25(18):5525-5536. PubMed ID: 31152021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of AUNIP as a candidate diagnostic and prognostic biomarker for oral squamous cell carcinoma.
    Yang Z; Liang X; Fu Y; Liu Y; Zheng L; Liu F; Li T; Yin X; Qiao X; Xu X
    EBioMedicine; 2019 Sep; 47():44-57. PubMed ID: 31409573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. APOBEC3A Expression in Penile Squamous Cell Carcinoma.
    Heller M; Prigge ES; Kaczorowski A; von Knebel Doeberitz M; Hohenfellner M; Duensing S
    Pathobiology; 2018; 85(3):169-178. PubMed ID: 29166639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Roles of APOBEC3A and APOBEC3B in Human Papillomavirus Infection and Disease Progression.
    Warren CJ; Westrich JA; Doorslaer KV; Pyeon D
    Viruses; 2017 Aug; 9(8):. PubMed ID: 28825669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Involvement of APOBEC3B in mutation induction by irradiation.
    Saito Y; Miura H; Takahashi N; Kuwahara Y; Yamamoto Y; Fukumoto M; Yamamoto F
    J Radiat Res; 2020 Nov; 61(6):819-827. PubMed ID: 32880638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of APOBEC3 expression as prognostic marker in squamous cell carcinoma of the penis.
    Trimmel B; Oszwald A; Diemand C; Ertl IE; Lemberger U; Bruchbacher A; Brettner R; Korn S; Resch I; Comperat E; Shariat SF; Hassler MR
    Sci Rep; 2022 Jul; 12(1):12911. PubMed ID: 35902635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aberrantly hypermethylated tumor suppressor genes were identified in oral squamous cell carcinoma (OSCC).
    Kim SY; Han YK; Song JM; Lee CH; Kang K; Yi JM; Park HR
    Clin Epigenetics; 2019 Aug; 11(1):116. PubMed ID: 31405379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells.
    Oliveira-Costa JP; de Carvalho AF; da Silveira da GG; Amaya P; Wu Y; Park KJ; Gigliola MP; Lustberg M; Buim ME; Ferreira EN; Kowalski LP; Chalmers JJ; Soares FA; Carraro DM; Ribeiro-Silva A
    Oncotarget; 2015 Aug; 6(25):20902-20. PubMed ID: 26041877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.